Primary source: View
The EPAR for Gardasil 9 has undergone revisions, impacting the labeling that reflects updated safety and efficacy information.
The revisions in the EPAR will influence the labeling of Gardasil 9, ensuring that it accurately reflects the latest safety, efficacy information, and guidance for the users, thereby safeguarding public health.
Update labeling materials for Gardasil 9 to incorporate new safety and efficacy data as per the revised EPAR.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Update labeling materials for Gardasil 9 to incorporate new safety and efficacy data as per the revised EPAR.
Gardasil 9 has received authorization for use in the EU, aimed at providing vaccination against various Human Papillomavirus (HPV) types leading to significant health issues. The updated EPAR reflects changes in labeling based on safety and efficacy information.
What changed: The EPAR for Gardasil 9 has undergone revisions, impacting the labeling that reflects updated safety and efficacy information.
Why it matters: The revisions in the EPAR will influence the labeling of Gardasil 9, ensuring that it accurately reflects the latest safety, efficacy information, and guidance for the users, thereby safeguarding public health.
Practical implication: Update labeling materials for Gardasil 9 to incorporate new safety and efficacy data as per the revised EPAR.
Published from the regulator source ingestion pipeline after PV impact triage.
The pharmacovigilance department must increase reporting obligations for any adverse effects related to Rezolsta as part of ongoing safety monitoring.
Healthcare professionals must administer Kavigale in a monitored clinical environment to manage potential severe allergic reactions, including anaphylaxis.
Implement resource allocation for increased monitoring of reported adverse reactions specific to Vislyfa as per the new safety evaluation requirements.
Stakeholders must review and update the labeling of Benlysta in accordance with the new indications highlighted in the EPAR.
